GlassScriptPhysician profile
Robert Joseph Olk
NPI 1265429245
$7,614.58
in general payments reported to CMS, 2019-2025
24 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $851 · 2021: $1,334 · 2022: $1,100 · 2023: $907 · 2024: $1,331 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,734.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $1,778.52 | 2019-2024 | Yutiq, Iluvien |
| Astellas Pharma US INC | $796.79 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $657.12 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $583.89 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $553.60 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Allergan, INC. | $488.38 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $383.73 | 2024-2025 | Acthar |
| Genentech USA, INC. | $334.79 | 2019-2025 | Vabysmo |
| Abbvie INC. | $281.16 | 2022-2025 | |
| Eyepoint US, INC. | $262.93 | 2019-2023 | |
| Biogen, INC. | $262.90 | 2022-2024 | Byooviz |
| Biotissue Holdings INC. | $241.76 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $167.89 | 2019-2023 | Eylea |
| Novartis Pharmaceuticals Corporation | $132.21 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $127.17 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $121.17 | 2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $98.99 | 2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Harrow Eye, LLC | $71.55 | 2023-2025 | Iheezo |
| Eyevance Pharmaceuticals LLC | $69.86 | 2020-2022 | |
| Alcon Vision LLC | $60.59 | 2019-2023 | Simbrinza |
| Coherus Oncology, INC. | $51.74 | 2023 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Glaukos Corporation | $31.97 | 2023 | |
| Mallinckrodt Enterprises LLC | $17.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Olk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.